Following an 8 year academic career at The University of Melbourne, in 1996 Dr Nash joined the ASX listed biotechnology company Zenyth Therapeutics (then AMRAD Corporation) as a senior scientist and subsequently held a number of positions including Director of Biologicals Research and Chief Scientific Officer. In July of 2005 he was appointed Chief Executive Officer of Zenyth, which was subsequently acquired by CSL Limited in November 2006. As Senior Vice President, Research at CSL he was responsible for the strategic and scientific leadership of Global Research activity. Dr Nash was appointed as CSL’s Chief Scientific Officer in 2020 and retired in March of 2025. He was elected as a Fellow of the Academy of Technological Sciences and Engineering in 2021, and as a Fellow of the Australian Academy of Science in 2025. He was the inaugural Chair of Jumar Bioincubator and is currently a Board Director at the Burnet Institute, Brandon BioCatalyst and Denteric.